Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Clinical trial NCT06318897 · RECRUITING

Trial details

NCT number: NCT06318897
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Start date: 2024-05-29
Primary completion: 2027-09-30
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.